Showing results (51-60 of 68) with videos related to
Sort By:
Pageof 7
Multiple Sclerosis and Related Disorders|August 13, 2015
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisEdward Fox, Keith Edwards, Gordon Burch, et al.Breast Cancer Research and Treatment|September 27, 2007
Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancerOrla Mc Cormack, Wen Y Chung, Patricia Fitzpatrick, et al.Journal of Neuroimmunology|May 12, 2019
B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patientsAmy E Lovett-Racke, Matthew Gormley, Yue Liu, et al.The Lancet. Neurology|April 26, 2020
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAnthony Traboulsee, Benjamin M Greenberg, Jeffrey L Bennett, et al.Neurology and Therapy|March 5, 2026
Efficacy of Ublituximab in People with Highly Active Relapsing Multiple SclerosisHans-Peter Hartung, Derrick Robertson, Lawrence Steinman, et al.Neurology and Therapy|December 19, 2022
Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS TrialAmit Bar-Or, Xavier Montalban, Xixi Hu, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|May 1, 2020
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosisEdward Fox, Amy E Lovett-Racke, Matthew Gormley, et al.JAMA Neurology|February 16, 2026
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension StudyBruce A C Cree, Edward Fox, Hans-Peter Hartung, et al.Blood|January 11, 2008
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cellsEllen Weisberg, Lolita Banerji, Renee D Wright, et al.Clinical Lymphoma & Myeloma|February 28, 2007
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapyEvdoxia Hatjiharissi, Mark Hansen, Daniel Ditzel Santos, et al.Pageof 7